Tailored Therapy for Clarithromycin-Resistant H. Pylori
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure.
Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has
been studied recently, however, there have been few studies comparing treatment regimen in
patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin
resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline,
metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin)
regimen in patient with clarithromycin-resistant H. pylori.